Why the study?
Does amlodipine added to hydrochlorothiazide reduce blood pressure in patients with essential hypertension inadequately controlled on hydrochlorothiazide alone?
Does amlodipine added to hydrochlorothiazide reduce blood pressure in patients with essential hypertension inadequately controlled on hydrochlorothiazide alone?
Amlodipine is an effective and safe add-on therapy for patients with mild to moderate essential hypertension inadequately controlled on hydrochlorothiazide alone.
Answers are grounded in this paper and cite their sources.
Supports adding amlodipine to hydrochlorothiazide for uncontrolled essential hypertension; confirms additive BP reduction in this RCT.
We compared amlodipine, a dihydropyridine calcium antagonist, to placebo as add-on therapy to hydrochlorothiazide in 91 hypertensive patients inadequately controlled on hydrochlorothiazide (50 mg/d for four weeks). This was a double-blind, randomized, multicenter, parallel group-trial; 45 patients received placebo and 46 received amlodipine in doses of 2.5 to 10 mg qd (mean 9 mg/d). Supine blood pressure systolic/diastolic, mean +/- SE mm Hg) 24-hour postdose was significantly reduced by 14.2 +/- 2.3/11.7 +/- 1, compared to placebo, 4.5 +/- 2.7/5 +/- 1.2. Standing blood pressure was similarly reduced: amlodipine by 14 +/- 2.7/12.5 +/- 1.2; placebo by 3 +/- 2.1/5.8 +/- 1.2. This reduction in blood pressure was attained without any significant changes in pulse rate, EKG, and serum lipids (triglycerides were reduced in the amlodipine group by 42.9 mg/dL, P = .023). Only two patients had side effects requiring discontinuation from the study (both in the amlodipine group). Side effects occurred in 27 amlodipine-treated patients (11 with peripheral edema) and 18 patients in the placebo (three with peripheral edema) group. Investigator's assessment of therapeutic effect and tolerability, and the percent of responders v nonresponders was also in favor of amlodipine. Thus amlodipine administered once daily is an effective and safe agent for second-step therapy in mild to moderate essential hypertension.
No takes yet. Share an insight, caveat, or question.
Glasser et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: